Most adults that have consumed cannabis have done it to ease health and wellness purposes, according to a new survey by The Harris Poll on behalf of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF).
On Wednesday, the leading cannabis producer published the results of a 2,000 people survey looking into the reasons that lead people to consume cannabis.
It found that 91 per cent of adults who have consumed it did it because of health or wellness reasons while 62 per cent said they rather use cannabis than pharmaceuticals when treating a medical issue.
The survey analysts found that 75 per cent of Americans say they rather use holistic solutions over pharmaceuticals to treat a medical issue.
Around 52 per cent use it for sleep, 49 per cent as a sleeping aid, 44 per cent to reduce stress and 41 to reduce anxiety.
The survey also found that 88 per cent of those who have consumed cannabis for health purposes feel it has improved their overall well-being. and 86 per cent of those who did it, would recommend it to a friend or family member.
Curaleaf says that as cannabis legalization continues to sweep the United States, beliefs and behaviours surrounding consumption are shifting to become more mainstream and inclusive for patients and consumers who rely on it for a variety of health and wellness needs – from helping to relieve menstrual cramps and arthritis to supporting stress and sleep issues.
Clinical cannabis pharmacist for Curaleaf New York Stacia Woodcock said education on how cannabis supports everyday health and wellness is critical to destigmatizing the plant and providing consumers with more choices to best fit their personal lifestyles.
“There are a wide variety of ways to consume cannabis safely, and many formulations actually have minimal intoxicating effects. Different product options with various ratios of THC and CBD give patients the opportunity to consume cannabis in a way that works with their lifestyle and comfort level,” said Woodcock.
Curaleaf operates in 22 states with 133 pot shops, 26 cultivation sites and over 5,700 employees. Its division Curaleaf International is one of the largest vertically integrated cannabis companies in Europe.
Company stock went down by 5.99 per cent on Wednesday to $7.53 on the Canadian Securities Exchange.